Look up one drug

Reason for Use code 651 For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections. Patients receiving concurrent administration with another anti-VEGF agent are not eligible for reimbursement. Treatment should be initiated with a loading phase of one injection per month for three consecutive months, followed by a maintenance phase. During the maintenance phase, patients should be monitored for best corrected visual acuity or continued disease activity. If there is clinical or diagnostic evidence of disease activity such as a loss of greater than 5 letters in visual acuity (Early Treatment Diabetic Retinopathy Score (ETDRS) chart or one Snellen line equivalent), ranibizumab may be administered. The interval between two doses should not be shorter than one month. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 652 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 11 percent. Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity. Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to DME and continued until stable visual acuity is reached again for three consecutive monthly assessments. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 653 For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity. Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to macular edema secondary to retinal vein occlusion and continued until stable visual acuity is reached again for three consecutive monthly assessments. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 654 For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Treatment is initiated with a single intravitreal injection. Monitoring is recommended monthly for the first 2 months and at least every 3 months thereafter during the first year. If monitoring reveals signs of disease activity (e.g. reduced visual acuity and/or signs of lesion activity), further treatment is recommended at a frequency of 1 injection per month until no disease activity is seen. Coverage limit: LU Authorization Period: 1 year

Byooviz · DIN 02525852 Manufacturer: Samsung Bioepis Co. Ltd; listing date 2023-07-31 Health Canada: Marketed since 2025-11-07 · brand MELVIZO · ATC S01LA04 RANIBIZUMAB · form Solution · route Intravitreal · ingredients RANIBIZUMAB 10 MG/ML · company Samsung bioepis co., ltd · schedule Prescription, Schedule d

DIN 02525852: Byooviz Raw flags: sec12=Y, sec3=Y Item: 523600151; group id 639; item number 1611; lccId 00372; manufacturer id SAM Source form: Inj Sol-0.23mL Vial Pk (Preservative-Free); strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $900.0000; ministry $900.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525852 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101483

Shortage status: active shortage (reported 2026-01-01, estimated to end 2027-06-30, last updated 2026-06-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525852

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 651 For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections. Patients receiving concurrent administration with another anti-VEGF agent are not eligible for reimbursement. Treatment should be initiated with a loading phase of one injection per month for three consecutive months, followed by a maintenance phase. During the maintenance phase, patients should be monitored for best corrected visual acuity or continued disease activity. If there is clinical or diagnostic evidence of disease activity such as a loss of greater than 5 letters in visual acuity (Early Treatment Diabetic Retinopathy Score (ETDRS) chart or one Snellen line equivalent), ranibizumab may be administered. The interval between two doses should not be shorter than one month. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 652 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 11 percent. Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity. Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to DME and continued until stable visual acuity is reached again for three consecutive monthly assessments. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 653 For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity. Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to macular edema secondary to retinal vein occlusion and continued until stable visual acuity is reached again for three consecutive monthly assessments. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 654 For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Treatment is initiated with a single intravitreal injection. Monitoring is recommended monthly for the first 2 months and at least every 3 months thereafter during the first year. If monitoring reveals signs of disease activity (e.g. reduced visual acuity and/or signs of lesion activity), further treatment is recommended at a frequency of 1 injection per month until no disease activity is seen. Coverage limit: LU Authorization Period: 1 year

Ranopto · DIN 02542250 Manufacturer: Teva Canada Innovation.; listing date 2024-03-28 Health Canada: Marketed since 2024-02-26 · brand RANOPTO · ATC S01LA04 RANIBIZUMAB · form Solution · route Intravitreal · ingredients RANIBIZUMAB 10 MG/ML · company Teva canada limited · schedule Schedule d, Prescription

DIN 02542250: Ranopto Raw flags: sec12=Y, sec3=Y Item: 523600152; group id 639; item number 1612; lccId 00372; manufacturer id TEI Source form: Inj Sol-0.23mL Vial Pk (Preservative-Free); strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $900.0000; ministry $900.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02542250 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103083

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542250

Shortage record checked 2026-09-13T08:10:21.292534+00:00